Zelira Therapeutics’ ZLT-L-007 Shows Promising Results in Diabetic Neuropathy Study

Zelira Therapeutics ( (AU:ZLD) ) has shared an update.

Zelira Therapeutics announced the publication of a clinical study demonstrating the efficacy and safety of its proprietary cannabinoid-based therapy, ZLT-L-007, in treating diabetic neuropathy. The study showed that ZLT-L-007 significantly outperformed Lyrica® (Pregabalin) in reducing pain and improving quality of life for patients, marking a potential shift in the standard-of-care treatment for diabetic neuropathy. The study, conducted under rigorous clinical standards, reported no serious adverse events, suggesting a promising future for ZLT-L-007 in the market.

More about Zelira Therapeutics

Zelira Therapeutics is a global leader in cannabinoid-based therapeutics, focusing on developing innovative treatments for various medical conditions. The company is particularly involved in creating therapies that address pain management and other symptoms associated with chronic illnesses.

Average Trading Volume: 3,615

Technical Sentiment Signal: Sell

Current Market Cap: A$4.88M

For an in-depth examination of ZLD stock, go to TipRanks’ Stock Analysis page.